Digital Phenotyping in Young Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

NACompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

March 3, 2025

Study Completion Date

March 3, 2025

Conditions
Breast Cancer
Interventions
DEVICE

Activity tracker

"Participants will receive a Withings Steel HR activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the NeoFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure NeoFit space."

Trial Locations (3)

92

Institut Curie, Saint-Cloud

51100

Institut Jean Godinot, Reims

75005

Institut Curie, Paris

All Listed Sponsors
lead

Institut Curie

OTHER

NCT05011721 - Digital Phenotyping in Young Breast Cancer Patients Treated With Neoadjuvant Chemotherapy | Biotech Hunter | Biotech Hunter